Syntax Research’s Pfizer PFE Stock Holding History

Syntax Research’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21K	Hold	871	–	–	0.02%	122
2026 Q1	$24.5K	Hold	871	–	–	0.02%	119
2025 Q4	$21.7K	Hold	871	–	–	0.01%	119
2025 Q3	$22.2K	Hold	871	–	–	0.01%	120
2025 Q2	$21.1K	Hold	871	–	–	0.02%	112
2025 Q1	$22.1K	Sell	871 -577	-40%	-$15.1K	0.02%	112
2024 Q4	$38.4K	Hold	1,448	–	–	0.03%	96
2024 Q3	$41.9K	Sell	1,448 -650	-31%	-$19K	0.03%	96
2024 Q2	$58.7K	Hold	2,098	–	–	0.05%	78
2024 Q1	$58.2K	Sell	2,098 -350	-14%	-$9.71K	0.04%	81
2023 Q4	$70.5K	Buy	2,448 +181	+8%	+$5.47K	0.06%	73
2023 Q3	$75.2K	Buy	+2,267	New	+$80.2K	0.06%	77

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Syntax Research's PFE Position: Q2 2026 in Review

Syntax Research held its Pfizer (PFE) position steady in Q2 2026 at 871 shares worth $21K. The position accounts for 0.02% of the portfolio, ranked #122.

Syntax Research first reported a position in PFE in Q3 2023 and has held it in 12 quarters since. The position peaked at $75.2K in Q3 2023. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Syntax Research held 871 shares of Pfizer worth $21K as of Q2 2026.
Syntax Research left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.02% of Syntax Research's portfolio in Q2 2026, its #122 holding.
Syntax Research first reported a position in Pfizer in Q3 2023 and has held it in 12 quarters since.
Syntax Research's Pfizer position peaked at $75.2K in Q3 2023.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Syntax Research's 13F filing for Q2 2026, filed 31 Jul 2026.